BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis

FRA:BRM • US1101221083

51.13 EUR
-0.2 (-0.39%)
Last: Feb 12, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

4

BRM gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 55 industry peers in the Pharmaceuticals industry. BRM has only an average score on both its financial health and profitability. BRM is cheap, but on the other hand it scores bad on growth. BRM also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • BRM had positive earnings in the past year.
  • BRM had a positive operating cash flow in the past year.
  • In multiple years BRM reported negative net income over the last 5 years.
  • BRM had a positive operating cash flow in 4 of the past 5 years.
BRM.DE Yearly Net Income VS EBIT VS OCF VS FCFBRM.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B -5B 10B 15B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 6.23%, BRM is in line with its industry, outperforming 50.91% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 32.55%, BRM is in the better half of the industry, outperforming 78.18% of the companies in the same industry.
  • With a decent Return On Invested Capital value of 16.42%, BRM is doing good in the industry, outperforming 72.73% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for BRM is below the industry average of 14.21%.
  • The last Return On Invested Capital (16.42%) for BRM is above the 3 year average (10.96%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 6.23%
ROE 32.55%
ROIC 16.42%
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
BRM.DE Yearly ROA, ROE, ROICBRM.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

  • BRM's Profit Margin of 12.57% is in line compared to the rest of the industry. BRM outperforms 47.27% of its industry peers.
  • BRM has a better Operating Margin (33.51%) than 80.00% of its industry peers.
  • BRM's Operating Margin has declined in the last couple of years.
  • BRM has a Gross Margin (73.15%) which is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of BRM has remained more or less at the same level.
Industry RankSector Rank
OM 33.51%
PM (TTM) 12.57%
GM 73.15%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
BRM.DE Yearly Profit, Operating, Gross MarginsBRM.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BRM is creating value.
  • There is no outstanding debt for BRM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BRM.DE Yearly Shares OutstandingBRM.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B
BRM.DE Yearly Total Debt VS Total AssetsBRM.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

  • An Altman-Z score of 2.33 indicates that BRM is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.33, BRM is in line with its industry, outperforming 43.64% of the companies in the same industry.
  • BRM has a debt to FCF ratio of 3.20. This is a good value and a sign of high solvency as BRM would need 3.20 years to pay back of all of its debts.
  • BRM's Debt to FCF ratio of 3.20 is fine compared to the rest of the industry. BRM outperforms 65.45% of its industry peers.
  • BRM has a Debt/Equity ratio of 2.41. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 2.41, BRM is doing worse than 83.64% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.41
Debt/FCF 3.2
Altman-Z 2.33
ROIC/WACC1.92
WACC8.55%
BRM.DE Yearly LT Debt VS Equity VS FCFBRM.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B 50B

2.3 Liquidity

  • BRM has a Current Ratio of 1.27. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of BRM (1.27) is worse than 61.82% of its industry peers.
  • BRM has a Quick Ratio of 1.17. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of BRM (1.17) is better than 67.27% of its industry peers.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.17
BRM.DE Yearly Current Assets VS Current LiabilitesBRM.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 439.47% over the past year.
  • Measured over the past years, BRM shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.92% on average per year.
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1.3%

3.2 Future

  • BRM is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.16% yearly.
  • The Revenue is expected to decrease by -5.36% on average over the next years.
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-3.16%
Revenue Next Year-7.97%
Revenue Next 2Y-5.07%
Revenue Next 3Y-5.93%
Revenue Next 5Y-5.36%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BRM.DE Yearly Revenue VS EstimatesBRM.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B 40B
BRM.DE Yearly EPS VS EstimatesBRM.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 9.87, the valuation of BRM can be described as reasonable.
  • Based on the Price/Earnings ratio, BRM is valued cheaper than 89.09% of the companies in the same industry.
  • BRM's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.67.
  • A Price/Forward Earnings ratio of 9.98 indicates a reasonable valuation of BRM.
  • Based on the Price/Forward Earnings ratio, BRM is valued cheaply inside the industry as 83.64% of the companies are valued more expensively.
  • BRM's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.69.
Industry RankSector Rank
PE 9.87
Fwd PE 9.98
BRM.DE Price Earnings VS Forward Price EarningsBRM.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BRM is valued cheaper than 90.91% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, BRM is valued cheaply inside the industry as 98.18% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 8.08
EV/EBITDA 7.38
BRM.DE Per share dataBRM.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

  • BRM's earnings are expected to decrease with -3.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 4.23%, BRM is a good candidate for dividend investing.
  • BRM's Dividend Yield is rather good when compared to the industry average which is at 1.94. BRM pays more dividend than 87.27% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.80, BRM pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.23%

5.2 History

  • On average, the dividend of BRM grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
BRM.DE Yearly Dividends per shareBRM.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

5.3 Sustainability

  • BRM pays out 82.81% of its income as dividend. This is not a sustainable payout ratio.
  • The Dividend Rate of BRM has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
DP82.81%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
BRM.DE Yearly Income VS Free CF VS DividendBRM.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B -5B 10B 15B
BRM.DE Dividend Payout.BRM.DE Dividend Payout, showing the Payout Ratio.BRM.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

BRISTOL-MYERS SQUIBB CO

FRA:BRM (2/12/2026, 7:00:00 PM)

51.13

-0.2 (-0.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05
Earnings (Next)04-30
Inst Owners81.87%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap104.09B
Revenue(TTM)N/A
Net Income(TTM)6.04B
Analysts70
Price Target48.84 (-4.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.23%
Yearly Dividend2.05
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)3.55%
PT rev (3m)7.28%
EPS NQ rev (1m)-32.94%
EPS NQ rev (3m)-32.35%
EPS NY rev (1m)-8.07%
EPS NY rev (3m)-7.12%
Revenue NQ rev (1m)0.44%
Revenue NQ rev (3m)-0.02%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)0.65%
Valuation
Industry RankSector Rank
PE 9.87
Fwd PE 9.98
P/S 2.57
P/FCF 8.08
P/OCF 7.44
P/B 6.66
P/tB N/A
EV/EBITDA 7.38
EPS(TTM)5.18
EY10.13%
EPS(NY)5.12
Fwd EY10.02%
FCF(TTM)6.33
FCFY12.38%
OCF(TTM)6.88
OCFY13.45%
SpS19.87
BVpS7.67
TBVpS-9.79
PEG (NY)N/A
PEG (5Y)N/A
Graham Number29.91
Profitability
Industry RankSector Rank
ROA 6.23%
ROE 32.55%
ROCE 23.41%
ROIC 16.42%
ROICexc 21.58%
ROICexgc 109.99%
OM 33.51%
PM (TTM) 12.57%
GM 73.15%
FCFM 31.86%
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.99%
ROICexgc(3y)70.36%
ROICexgc(5y)72.03%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score6
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 2.41
Debt/FCF 3.2
Debt/EBITDA 2.13
Cap/Depr 26.84%
Cap/Sales 2.75%
Interest Coverage 7.66
Cash Conversion 79.11%
Profit Quality 253.39%
Current Ratio 1.27
Quick Ratio 1.17
Altman-Z 2.33
F-Score6
WACC8.55%
ROIC/WACC1.92
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-3.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1.3%
Revenue Next Year-7.97%
Revenue Next 2Y-5.07%
Revenue Next 3Y-5.93%
Revenue Next 5Y-5.36%
EBIT growth 1Y44.7%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year220.11%
EBIT Next 3Y49.61%
EBIT Next 5Y23.19%
FCF growth 1Y30.91%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y28.71%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%

BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ

What is the fundamental rating for BRM stock?

ChartMill assigns a fundamental rating of 4 / 10 to BRM.DE.


What is the valuation status of BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?

ChartMill assigns a valuation rating of 7 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.


How profitable is BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?

BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 4 / 10.


What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?

The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to decline by -1.05% in the next year.


Is the dividend of BRISTOL-MYERS SQUIBB CO sustainable?

The dividend rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 7 / 10 and the dividend payout ratio is 82.81%.